Grants or venture capital
Should a startup pursue grants or venture capital?
They answer different questions, so for most companies this is a sequencing decision rather than a choice. A grant funds specific work, takes no ownership, and runs on the funder's timetable. Venture capital funds the company generally, takes ownership, and moves at deal speed. The pattern that works: use non-dilutive money to retire technical risk while the company is cheapest, which raises the value of every share you sell later. The pattern that fails: treating grants as a substitute for revenue or a bridge for a company that needs money in six weeks, because grant calendars do not care about your runway.
Last reviewed August 28, 2026.
What each one actually buys and costs
- Ownership
- A grant takes none. An equity round takes the share you negotiate, forever, and the option pool and preferences that come with it. This is the whole argument for non-dilutive money and it is as strong as it sounds, within the limits below.
- Speed and certainty
- Venture money can close in weeks when there is conviction. A grant competition has a submission window, a review period and a start date, none of which you control. Companies die waiting for decisions that were never going to arrive in time.
- What the money may be spent on
- An investor funds the company: payroll, marketing, pivots, whatever the quarter needs. A grant funds the proposed work, and spending it otherwise is not a pivot, it is a compliance problem with a federal agency.
- What arrives besides money
- Investors bring networks, pressure and help, in proportions that vary by investor. A federal award brings a different asset: a signal. An agency that put money on your technology after competitive review is diligence another buyer did for free, and investors read it that way.
- Who is eligible
- Anyone can pitch an investor. SBIR eligibility has ownership rules, including limits on venture ownership at some agencies, which is itself a sequencing argument: the program is easiest to access before the large raise, not after.
The sequencing argument
Dilution costs the most when the company is worth the least. The riskiest, cheapest phase of a technical company is exactly the phase research grants exist to fund, so every milestone retired on grant money is a milestone you did not sell equity to reach.
This is why the strongest deep tech companies frequently do both, in order: non-dilutive money through the science risk, equity money for the scaling that grants cannot fund. The two are complements in a capital plan, and the founders who treat them as rivals usually end up with the weaker version of whichever one they chose.
Knowing what is actually open before you decide
The sequencing decision needs one input most founders do not have: what non-dilutive money is actually available to this company, now. Quillify answers that in one search across 4,000+ open grants and 11,000+ contract opportunities, matched to a plain-language description of the work, with the deadlines on a calendar. Whether to raise is your call; what exists should not be a guess.
Who asks this most
The answer above is the same whoever you are. What Quillify does about it is not.
Related
- Non-dilutive fundingWhat is non-dilutive funding and where does a company get it?
- SBIR and STTRWhat are SBIR and STTR grants and who can apply?
- Grants for startupsAre there grants for startups, and which ones are real?
- The SBIR commercialization planWhat is an SBIR commercialization plan and what goes in it?
All guides, or the glossary.
Stop researching and see what you are eligible for.
Browsing and keyword search are free, and there is no card required.